Four Bills Would Enable Taxpayer Contributions to Cancer Research

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 7
Volume 10
Issue 7

WASHINGTON-House members have introduced four bills that would enable taxpayers to support cancer research: One bill would allow a check-off box on income tax forms to provide contributions to a new Breast and Prostate Cancer Research Fund. Two bills would permit taxpayers to designate part or all of their income tax refund to research, either through the National Institutes of Health or the Department of Veterans’ Affairs. The last bill would authorize a matching grants program to encourage states to sell special license plates to provide funds for breast cancer research.

WASHINGTON—House members have introduced four bills that would enable taxpayers to support cancer research: One bill would allow a check-off box on income tax forms to provide contributions to a new Breast and Prostate Cancer Research Fund. Two bills would permit taxpayers to designate part or all of their income tax refund to research, either through the National Institutes of Health or the Department of Veterans’ Affairs. The last bill would authorize a matching grants program to encourage states to sell special license plates to provide funds for breast cancer research.

Recent Videos
According to Aditya Bardia, MD, MPH, FASCO, antibody-drug conjugates are slowly replacing chemotherapy as a standard treatment for breast cancer.
A simulation procedure helped to ascertain chemotherapy tolerability before administering radioembolization therapy for NETs with liver metastases.
The addition of radioembolization to radiosensitizing chemotherapy may help concurrently treat patients with liver tumors and disease outside the liver.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Decreasing the low-dose bath of proton therapy to the body may limit the impact of radiation on lymphocytes and affect tumor response.
4 experts are featured in this series.
4 experts are featured in this series.
According to Eyub Akdemir, MD, reducing EDIC may be feasible without compromising target coverage to reduce anticipated lymphopenia rates.
7 experts are featured in this series.
Related Content